Corrections:

Xiuhui Shi^1,*, Hang Zhang^1,*, Min Wang^1,*, Xiaodong Xu¹, Yan Zhao¹, Ruizhi He¹, Min Zhang¹, Min Zhou¹, Xu Li¹, Feng Peng¹, Chengjian Shi¹, Ming Shen¹, Xin Wang¹, Xingjun Guo¹ and Renyi Qin¹

¹Department of Biliary-Pancreatic Surgery, Affiliated Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
^*These authors have contributed equally to this study

Published: May 19, 2022

Copyright: © 2022 Shi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: In Figure 4D, the image of TFK-1 in the ‘shControl’ column contains an accidental overlap of the image of TFK-1 in the ‘shAFAP1-AS1’ column of Figure 4E. The corrected Figure 4, produced using the original data, is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2017; 8:58394–58404. DOI: https://doi.org/10.18632/oncotarget.16880

Figure 4: Inhibition of AFAP1-AS1 impairs tumorigencity of CCA cell lines in vivo. (D, E) Representative images of IHC staining showing expression of Ki67 and PCNA in xenograft tumor tissues from the shAFAP1-AS1 group or shControl group. *P < 0.05, **P < 0.01 and ***P < 0.001, Student’s t-test.